What are your top takeaways in Hematologic Malignancies from ASH 2025?

1. The PARADIGM study is a very important one that may result in a paradigm change for the treatment of AML. The study showed that outcomes are equal or better with AZA + VEN among patients with AML suitable for intensive chemotherapy. The efficacy was superior in response rate and EFS (but not overall...

• AML - Promise with use of HMA venetoclax as a bridge to transplant even in young and fit patients (age <60 who are not NPM1 mutated, not FLT3 mutated, and do not have CBF leukemia) based on a paradigm phase 2 randomized multicenter study.
• AML - use of triplets with IDH1 inhibitor or menin inhibitor...

Results from PARADIGM - a phase II randomized multicenter study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with Acute Myeloid Leukemia.

1. Abstract 645 - Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial: As blinatumomab becomes increasingly incorporated into the frontline treatment of B-cell ALL, it is vitally important to assess inotuzumab ozogamicin (InO)-based therapies in the relapse...

• Certainly, the PARADIGM trial at the plenary created food for thought.
• I was also very excited to see in vivo CAR-T in myeloma, the 1st abstract in the late-breaking session.
• As well as CAR-T as consolidation in ALL.

For the 4th consecutive year, I attended the American Society of Hematology (ASH) meeting virtually. As the years pass, I am convinced this is the best and most efficient way for me to get the most out of ASH. I no longer rush from presentation to presentation, invariably arriving late, desperately ...

The PARADIGM study in the plenary session obviously which stirred a lot of controversy.

I see this work as potentially a step towards intensive chemo-free induction for many AML patients but with lots of reservations:

• Generalizing HMA/Ven for all fit/young patients with high-risk disease carries ...